Mycoplasma pneumoniae attachment to WiDr cell cultures: competitive inhibition assays. by Chandler, D. K. & Barile, M. F.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 56 (1983), 679-683
Mycoplasma pneumoniae Attachment to WiDr Cell
Cultures: Competitive Inhibition Assays
DONNA K.F. CHANDLER, Ph.D., AND MICHAEL F. BARILE, Ph.D.
Mycoplasma Branch, Office ofBiologics, Food and Drug Administration,
Bethesda, Maryland
Received January 4, 1983
Attachment of radiolabeled M. pneumoniae to human WiDr cell culture monolayers was
dependent on the WiDr cell density and the concentration of M. pneumoniae. Saturation of
confluent monolayers grown on 5 mm coverslips was attained with only 40 Ag of M.
pneumoniae protein. Preincubating the WiDr monolayers with unlabeled M. pneumoniae or
with a protein-rich extract prepared from M. pneumoniae inhibited subsequent attachment of
radiolabeled organisms. Attachment inhibition by the M. pneumoniae extract provided a
quantitative assay for mycoplasmal binding components. Treatment of radiolabeled M.
pneumoniae with orosomucoid, ceruloplasmin, andgangliosides inhibited attachment to WiDr
cells. These sialoglycoconjugates may be structural analogues of the target cell receptor.
INTRODUCTION
Attachment ofMycoplasmapneumoniae to mucosal tissues is an essential step in
initiating respiratory disease and may help to protect the mycoplasma from the
defense mechanisms of the host. Stimulation of host immune responses to
mycoplasma binding components should inhibit infection and provide an effective
means of preventing disease [1]. A protein-rich extract ofM. pneumoniae which ex-
hibits binding activity [2] is a potential source for the purification and characteriza-
tion of M. pneumoniae binding components. Comparative studies showed that
virulent strains ofM. pneumoniae readily attach to hamster tracheal organ cultures,
tracheal outgrowth monolayers, human erythrocytes, and WiDr human carcinoma
cell cultures [3]. However, the WiDr cell culture monolayers provided the most
useful cell substrate for quantitating attachment inhibition. This report summarizes
the WiDr monolayer micro-attachment assay and describes two applications of the
procedure: a quantitative assay for mycoplasmal binding components based on in-
hibition by the protein-rich extract, and characterization of target cell receptor ac-
tivities based on inhibition by gangliosides and sialic acid-containing glycoproteins.
MATERIALS AND METHODS
M. pneumoniae cultures were grown and labeled with 3H-palmitic acid as
previously described [3,4]. The micro-attachment assay utilized human carcinoma
WiDr cell cultures on 5 mm coverslips (105 cells per microtiter well) as previously
described [4]. The WiDr cell monolayers were incubated at 36°C with 5-80,tg of
radiolabeled M. pneumoniae cell protein for one hour, the monolayers were washed,
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and the washed monolayers with adherent radiolabeled mycoplasmas were counted
by liquid scintillation spectrometry.
Inhibition studies were carried out in the following manner: WiDr cells were
preincubated with unlabeled mycoplasma suspensions or with the extract prepared
by treating M. pneumoniae with 2 M NaCl [2]. Suspensions of radiolabeled M.
pneumoniae were then added and the standard attachment assays were performed.
Binding component activity in the extract was calculated by subtracting the attach-
ment value obtained in the presence of extract from the control value obtained
without extract (Aattachment). To determine the receptor site activity of sialic acid-
containing glycoconjugates, the labeled M. pneumoniae suspension was prein-
cubated with gangliosides or sialic acid-containing glycoproteins for 30 minutes at
36°C. WiDr monolayers were then added, and attachment was determined with the
standard procedure [4]. Human ceruloplasmin was from Sigma Chemical Co. (St.
Louis, MO), and bovine brain gangliosides and human plasma orosomucoid were
from Calbiochem-Behring Corp. (La Jolla, CA).
RESULTS AND DISCUSSION
Micro-Assayfor M. pneumoniae Attachment to WiDr Cell Monolayers
Early experiments showed that cells in suspension were unsuitable for standard-
ized, reproducible attachment assays [3], and procedures were developed for using
cell culture monolayers in the assays. WiDr cells from a human intestinal carcinoma
were selected because they are of human origin and are epithelial-like [5]. A number
of cell cultures were screened for M. pneumoniae attachment using a DNA staining
procedure[6], andcomparative studies indicated that the WiDr cell line was superior
for M. pneumoniae attachment. The time course for the attachment of M.
pneumoniae to the WiDr cell monolayers at36°C showed that binding occurred in
one hour, while background attachment to control coverslips without cells was less
than 10 percent ofthe attachment to the monolayers [3]. An incubation time of one
hour was used in the standard attachment assay.
The micro-attachment assay was used to examine the attachment capacity of
radiolabeled strains PI-1428, M129, MAC, FH, and B176 [7]. The binding curves
for virulent strainsM129 andPI-1428, as well as for the laboratory strains MAC and
FH, were nearly identical. Saturation of the monolayers was obtained at approx-
imately 40jg of mycoplasmal protein per assay. However, attachment of avirulent
strain B176 was only 20-30 percent of the level obtained with the other strains.
WiDr cellmonolayers ofvarious cell densities were obtained by plating 6 x 103 to
2 x 105 cells per microtiter well on 5 mm coverslips. Attachment was proportional
to the number of WiDr cells added, and maximum attachment was achieved using
confluent monolayers (approximately 30,g of protein [8]) obtained with 105 cells
per well [4]. Themonolayer protein content was related to the number of cells added
to the wells and closely paralleled the attachment. Hence, standard attachment ac-
tivity was defined as ng of M. pneumoniae protein attached per tg of WiDr
monolayer protein, which allowed directcomparison ofdifferent experiments. With
10 to 20 Ag of M. pneumoniae added per monolayer, 4 to 8 percent of the
mycoplasmas adhered to the monolayers in one hour. Similar values were observed
for attachment to hamster tracheal organ cultures, tracheal outgrowth monolayers,
and human erythrocytes [3]. It is possible that only a fraction of the radiolabeled
mycoplasmas are capable of attaching to mammalian cells, as shown for the
adherence of M. gallisepticum to human erythrocytes [9].
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Attachment Inhibition: Assayfor Mycoplasmal Binding Components
Inhibition studies were performed by preincubating the WiDr monolayers with
unlabeled M. pneumoniae or the protein-rich extract. Radiolabeled M. pneumoniae
was then added as described for the standard attachment assay. The capacity of
unlabeled M. pneumoniae to inhibit attachment of 3H-M. pneumoniae was exam-
ined. When the WiDr monolayers were preincubated with equivalent amounts of
unlabeled organisms, subsequent attachment of radiolabeled mycoplasmas was in-
hibited by 50 to 60 percent [4].
We have described a protein-rich extract ofM. pneumoniae which has the capac-
ity to agglutinate human erythrocytes [2]. The extract was prepared by incubating
M. pneumoniae with 2 M NaCl followed by freeze-thaw, ultracentrifugation, and
dialysis and lyophilization of the supernatant [2]. The hemagglutinating activity of
the extract indicates that it contains solubilized mycoplasma binding components
which should inhibit attachment. Figure 1 demonstrates that M. pneumoniaeattach-
ment was progressively inhibited with increasing levels of the protein-rich extract.
To calculate binding component activity, the attachment in the presence of extract
was subtracted from the control value obtained without extract, as illustrated in Fig.
1. This difference, A attachment, can be calculated for each concentration ofextract
in the assay and provides an estimate of the binding capacity. The resultant hyper-
bolic dose-response curves show saturation of the monolayers by binding com-
ponents in the extract and closely resemble the binding curves obtained with
radiolabeled M. pneumoniae [4,7].
A major advantage ofthe micro-attachment procedure is its sensitivity for attach-
ment inhibition. Saturation was observed with only 40 jig of M. pneumoniae per
assay. Saturation at low levels of mycoplasma occurs because of the small number
of target cells, and hence limited receptor sites, contained in monolayers on small 5
mm coverslips. The resulting high ratio of mycoplasmas to host target cells permits
the solubilized binding components to compete effectively with labeled
mycoplasmas for the limited number of receptor sites. This conclusion is supported
by experimental data: attachment inhibition by the extract was low or not detectable
when saturation was not observed, i.e., when hamster tracheal organ cultures or
human erythrocytes were used as the target cells [3]. In contrast, inhibition by the
protein-rich extract was readily detectable when WiDr cell culture monolayers or
hamster tracheal outgrowth monolayers were used in the micro-attachment assay
ATTACHMENT INHIBITION BY EXTRACT
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41 FIG. 1. Attachment inhibition by M. pneumoniae
10ffi lo - \ protein-rich extract. WiDr monolayers containing 19 tsg
protein were preincubated with extract at the indicated con-
centrations for 60 minutes. Radiolabeled M. pneumoniae
(strain PI-1428, 11 tg, 1636 cpm/Ag protein) was then
added and attachment was determined with the standard
assay. A attachment for each concentration of extract was
-25 50 determined by subtracting the attachment in the presence of
EXTRCTADDED (pg protein) extract from the control value without extract.
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[3] Thus, the micro-attachment assay provides the appropriate mycoplasma/recep-
tor site ratio for quantitative inhibition studies.
It is noteworthy that the hyperbolic attachment curves obtained with the
mycoplasmal binding components as well as with the intact cells approximate the
Langmuir adsorption isotherms expected for receptor-ligand binding [10].
Moreover, the Lineweaver-Burke double reciprocal plots of the binding data from
these curves were linear [Chandler DKF: unpublished results]. These observations
provide further evidence that the attachment of radiolabeled mycoplasmas and the
attachment inhibition by binding components in the extract represent specific in-
teractions with receptor components of the WiDr cells.
Attachment Inhibition: Detection of Target Cell Receptor Analogues
Attachment inhibition was also observed when the radiolabeled M. pneumoniae
was treated with certain select sialoglycoconjugates. Figure 2 shows the results of
two experiments in which we examined attachment inhibition by transferrin,
ovalbumin, orosomucoid, gangliosides, and ceruloplasmin. Inhibition by transfer-
rin and ovalbumin was less than 20 percent, while attachment inhibition by
orosomucoid and gangliosides was 57 percent and 82 percent, respectively. In the
second experiment, the dose response for ceruloplasmin shows progressive inhibi-
tion with increasing concentration (data plotted from [4]).
Previous work has indicated that receptor sites on the host cell surface comprise
sialic acid-containing glycoconjugates [11-16]. Attachment of M. pneumoniae to
WiDr cells was inhibited by gangliosides, ceruloplasmin, and orosomucoid, which
supports this concept of the host cell receptor. Gangliosides, ceruloplasmin, and
orosomucoid are sialoglycoconjugates which may contain structural analogues of
the specific cell receptors that bind to the mycoplasmas, thereby blocking attach-
ment to target cells. Hence, the relative binding activities of these and other
sialoglycoconjugates may also provide information about the specificity of the
receptor sites.
CONCLUSIONS
The WiDr cell monolayer micro-attachment assay provides the appropriate
mycoplasma/receptor site ratio for quantitative inhibition studies and binding
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analyses. Mycoplasmal binding components in a protein-rich extract of M.
pneumoniae can be quantitated using the attachment inhibition assay, and the ex-
tract presents a suitable source for the characterization and purification ofthe bind-
ing components. The WiDr cell monolayer attachment inhibition assay can also
identify host cell receptor activities. Thus, the WiDr cell culture monolayers provide
an important in vitro model to examine M. pneumoniae attachment mechanisms.
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